Immpact Bio cleared to start clinical trial of IMPT-514 in SLE patients
Immpact Bio has been cleared in the U.S. to start testing its cell therapy IMPT-514 in people with active systemic lupus erythematosus (SLE) that is refractory, or resistant to treatment. The clearance by the U.S. Food and Drug Administration “marks a pivotal milestone for our autoimmune disease clinical…